3月28日,3月28日,神威药业(02877.HK)发布2024年度业绩公告,全年营业收入37.78亿元,同比下降16.4%;股东应占溢利(归母净利润)8.4亿元,同比下滑13.4%。董事会宣布派发2025年第一次中期股息每股36分。公告显示,受医药行业政策调整、市场竞争加剧等因素影响,公司主要产品线销售普遍承压。其中,注射液产品销售额同比下降29%,口服产品销售额下降8.1%。特别是呼吸类、感冒...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.